Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.65 |
| ▸ | CTSD | P07339 | 8/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877367 | 0.83 | BACE1 (0.60) | BACE1CTSDBACE2APP | |
| SCHEMBL6892761 | 0.81 | BACE1 (0.73) | BACE1CTSDBACE2APP | |
| SCHEMBL6892757 | 0.81 | BACE1 (0.73) | BACE1CTSDBACE2APP | |
| SCHEMBL5350048 | 0.80 | BACE1 (0.78) | BACE1CTSDBACE2 | |
| SCHEMBL5344273 | 0.80 | BACE1 (0.68) | BACE1CTSDBACE2 | |
| SCHEMBL5362382 | 0.79 | BACE1 (0.86) | BACE1CTSDBACE2 | |
| SCHEMBL5353972 | 0.79 | BACE1 (0.78) | BACE1CTSDBACE2 | |
| SCHEMBL13307525 | 0.79 | BACE1 (0.86) | BACE1CTSDBACE2 | |
| SCHEMBL5353223 | 0.79 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL3352669 | 0.78 | BACE1 (0.76) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203096-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | claimed |
| US-20020143177-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | claimed |
| US-7553831-B2 | Beta-secretase inhibitors; inhibiting cleavage of amyloid precursor protein (APP); hydroxy-functional disubstituted amines such as 6-(([[(2S,3S)-4-(3,5-difluorophenyl)-3-((3-[(dipropylamino)carbonyl]benzoyl)amino)-2-hydroxybutyl](ethyl)amino]carbonyl)amino)hexanoic acid | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20050203096-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| US-6846813-B2 | For inhibiting beta-secretase enzyme activity and A beta peptide production, inhibition of beta-secretase enzyme activity halts or reduces production of A beta from APP and reduces or eliminates the formation of beta-amyloid deposits | PHARMACIA & UPJOHN COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| US-20020143177-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143177-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, CHAT | BACE1 5/4885CTSD 1833/4885BACE2 8/4885 |
| US-20050203096-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | BACE1 7/4885CTSD 1651/4885BACE2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.